RSS   Newsletter   Contact   Advertise with us
Post Online Media

NeuroVive says COO position is no longer required

NeuroViveNeuroVive Pharmaceutical AB, a mitochondrial medicine company, announces that its chief operating officer, Jan Nilsson, leaves the company.

Mr. Nilsson also was a Director and for a period he acted as NeuroVive interim CEO. Mr. Nilsson has over 30 years of experience in senior management, commercial and sales roles in the pharmaceutical and biotechnology sectors in Sweden and internationally.

Article continues below

READ MORE NeuroVive names Magnus Hansson as chief medical officer

Since 2011 Mr. Nilsson has served as Managing Director of Lipopeptide AB and as Chief Commercial Officer at Pergamum AB, two clinical-stage Swedish biotech companies developing innovative wound treatments based on therapeutic peptides.

Between 2004 and 2009 he served as Managing Director of Tripep AB, a listed Swedish-biotech company developing therapeutic DNA-vaccines against hepatitis B and C.

Prior to that Mr. Nilsson spent several years at Schering-Plough where he served in a number of senior management, marketing and sales positions, including Vice-President for the Nordic region between 2000 and 2004. He has served on the Board of Directors of NeuroVive since 2011.

NeuroVive says that over the past several months, the business strategy and organization have been re-oriented to optimize the way forward. As one consequence the position of COO is no longer required.


 LATEST MOVES FROM Sweden 





More inside POST
 
 

We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy